Cutting-edge blood analysis service to realize use in healthcare

Finnish biotech Nightingale Health, which provides a comprehensive blood analysis service world-wide to universities and medical research institutions, has announced a pilot of its technology in the healthcare sector. The goal of the pilot, in partnership with Finnish health service provider Coronaria, is to verify that Nightingale’s service can be successfully applied within a healthcare setting.  

Nightingale's blood test can replace many routine blood tests currently used in healthcare (e.g. glucose tests). Additionally, Nightingale’s service provides other blood biomarkers that can enhance disease risk prediction. In the long-term, Nightingale plans to provide better tools for clinicians, enabling preventive healthcare for chronic diseases, such as diabetes and cardiovascular disease.  
"The only sustainable way to reduce the burden of chronic diseases is to invest in their prevention. The goal of this cooperative pilot with Coronaria is to prove Nightingale's technology's suitability for routine clinical use," said Nightingale Health's CEO Teemu Suna.  
The pilot's cooperative partner Coronaria is one of Finland's largest providers of healthcare services.  
"Coronaria aims to build a novel healthcare system in Finland that will benefit all of us, with patients receiving better care, personnel achieving more and society saving money. The emphasis in healthcare must be shifted to preventive and personalized care, especially for chronic disease treatments. We see Nightingale's blood analysis as an important tool to achieve this goal. As a result, we wanted to be the first to pilot the service in Finland", said Olli Karhi, member of the board of Cor Group.  


Teemu Suna
CEO, CO-founder
Nightingale Health Oy
p. +358 40 196 1669

About Nightingale Health

Nightingale Health Ltd. is the innovator of an internationally recognized NMR (Nuclear Magnetic Resonance) based biomarker analysis assay for early disease detection. Our aim is to solve the growing burden of cardiovascular disease and diabetes, accounting for healthcare costs of over 1.6 trillion dollars annually. Our pioneering precision medicine services, include: effective chronic disease screening, health diagnostics and improving treatment efficacy. By providing our customers with accurate health data, we plan to help empower patients to follow-up on their own well-being and take proactive steps to stay healthy.

For more information, please visit


About Us

Nightingale Health is a biotech company aiming to solve the global burden of chronic disease. We believe that rather than solely focusing on treatments, health should be about keeping people healthy. We develop pioneering solutions that facilitate active prevention of chronic diseases, such as cardiovascular diseases and diabetes. With our proprietary blood testing technology, we reveal unique molecular insights that are otherwise invisible using standard technologies. This broader visibility allows us to predict the future risk of a person developing a disease, empowering people to make a positive impact on their health.





"Coronaria  aims to  build a novel healthcare system  in  Finland  that will benefit  all  of us, with  patients receiving  better care, personnel  achieving more and  society saving  money. The emphasis in healthcare  must be shifted to preventive and  personalized  care, especially  for  chronic disease  treatments. We see Nightingale's blood analysis as  an  important tool to achieve this  goal.  As a result, we wanted  to be  the  first  to  pilot the service in Finland",
Olli Karhi, Coronaria, Cor Group
"The only sustainable way to reduce the burden of chronic diseases is to invest in their prevention. The goal of this cooperative  pilot with  Coronaria  is to prove Nightingale's technology's suitability  for  routine  clinical  use"
Teemu Suna, CEO, Co-founder, Nightingale Health